News & Resources

Follow all the latest from Fresenius Kabi biosimilars

Jump to:

Latest News

Fresenius Continues its Biopharma Momentum with Launch of Subcutaneous Formulation of Tyenne® (tocilizumab-aazg) in the United States

Fresenius Kabi announced today the immediate availability in the U.S. of its biosimilar Tyenne® (tocilizumab-aazg), in a subcutaneous formulation, which will increase access to affordable and cost-effective treatment options for use in the treatment in chronic autoimmune diseases.

Read More

Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®, its Third Approved Biosimilar in the U.S.

Tyenne® is the first tocilizumab biosimilar by Fresenius Kabi with an intravenous and subcutaneous formulation approved by the FDA. The tocilizumab biosimilar provides increased access and an affordable, high-quality, and safe treatment option for U.S. patients.

Read More

Fresenius Kabi’s Biosimilar Tyenne® (tocilizumab-aazg) becomes the first IV and Subcutaneous tocilizumab biosimilar approved by the FDA

Tyenne® provides a comprehensive, accessible, and high-quality treatment option for U.S. patients treated with tocilizumab.

Read More

Upcoming Events


October 23-25, 2023

Connect with us in St. Louis at the Fall Hospital Pharmacy Conference.

Set up a time to meet

Chicago Race for the Cure

October 28, 2023

Connect with us in Chicago’s Soldier Field for the Susan G. Komen Race for the Cure.

Set up a time to meet

ASHP Mid-Year

December 3-7, 2023

Connect with us in Anaheim at the American Society of Health-System Pharmacists Mid-year Meeting.

Set up a time to meet


December 14-16, 2023

See us in Orlando at the Advances in Inflammatory Bowel Diseases Conference.

Set up a time to meet